Imunexus Therapeutics
Bundoora, Australia · imunexus.com
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Imunexus Therapeutics Ltd is an Australian biotechnology company developing multispecific biologic medicines for serious diseases. Its lead program, IMX39, is being developed for multiple sclerosis, and its pipeline also spans oncology, rare disease, and regenerative medicine.
They take quote requests by email.
What they offer
Imunexin™ platform development
Develops a patented platform that adds engineered protein modules to existing biologic drugs to create multispecific therapies.
Multispecific biologic drug development
Develops next-generation biologic medicines designed to act on multiple biological pathways within a single therapy.
Strategic biologics partnerships
Supports collaborations to enhance existing biologic drugs using the imunexin™ platform.
What they work on
- Modalities
- Antibody, Bispecific, Peptide, Cell therapy, Recombinant protein
- Therapeutic areas
- multiple sclerosis, neurology, oncology, rare disease, regenerative medicine, small cell lung cancer, Gaucher’s disease
- Sites
- Bundoora, Australia
Similar labs. Abnova, Myriotx, Oncodesign Services, ORF Biologics
Found in a contract services directory. Listing built from imunexus.com. Work here? Claim this listing.